The Effects of the DPPIV Inhibitor Sitagliptin in Cystic Fibrosis-related Diabetes

Trial Profile

The Effects of the DPPIV Inhibitor Sitagliptin in Cystic Fibrosis-related Diabetes

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2014

At a glance

  • Drugs Sitagliptin (Primary)
  • Indications Diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Dec 2011 Planned End Date changed from 1 Jul 2011 to 1 Jul 2012 as reported by ClinicalTrials.gov.
    • 15 Dec 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top